Skip to main content
Erschienen in: Skeletal Radiology 9/2016

26.05.2016 | Scientific Article

Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: systematic review and meta-analysis

verfasst von: Tadahiko Kubo, Taisuke Furuta, Muhammad P. Johan, Nobuo Adachi, Mitsuo Ochi

Erschienen in: Skeletal Radiology | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

The objective of this systematic review is to provide an up-to-date and unprecedented summary of percent slope analysis of dynamic magnetic resonance imaging (MRI) for the preoperative evaluation of the chemotherapy response of osteosarcoma or Ewing sarcoma.

Materials and method

Studies evaluating dynamic MRI for the preoperative evaluation of the chemotherapy response of osteosarcoma or Ewing sarcoma were systematically searched for in MEDLINE, EMBASE, and Web of Science. More than 60 % reduction of the slope of the time intensity curve derived from dynamic MRI was defined as a positive response. Pooled sensitivity and specificity for each study were calculated into 2 × 2 contingency tables. The DerSimonian-Laird random-effects method was used for determining the pooled diagnostic odds ratio and the area under curve (AUC) of the summary receiver operating characteristic (SROC) curve.

Results

A total of six studies with 66 patients who fulfilled all of the inclusion criteria were considered for the meta-analysis. The pooled sensitivity and specificity were 0.73 (95 % CI, 0.54–0.88) and 0.83 (95 % CI, 0.67–0.94), respectively. A significant difference was found between the good and poor responders in the diagnostic odds ratio. The SROC curve showed that the AUC was 0.839, indicating diagnostic accuracy in estimating good therapy response.

Conclusion

The slope of the time intensity curve derived from dynamic MRI was useful for evaluating the histological response of patients to neoadjuvant chemotherapy in osteosarcoma or Ewing sarcoma.
Literatur
1.
Zurück zum Zitat Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol. 2001;19:1818–29.PubMed Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol. 2001;19:1818–29.PubMed
2.
Zurück zum Zitat Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2001;20:776–90.CrossRef Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2001;20:776–90.CrossRef
3.
Zurück zum Zitat Eselgrim M, Grunert H, Kühne T, et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer. 2006;47:42–50.CrossRefPubMed Eselgrim M, Grunert H, Kühne T, et al. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer. 2006;47:42–50.CrossRefPubMed
4.
Zurück zum Zitat Grohar PJ, Helman LJ. Prospects and challenges for the development of new therapies for Ewing sarcoma. Pharmacol Ther. 2013;137:216–24.CrossRefPubMed Grohar PJ, Helman LJ. Prospects and challenges for the development of new therapies for Ewing sarcoma. Pharmacol Ther. 2013;137:216–24.CrossRefPubMed
5.
Zurück zum Zitat Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment: where do we stand? A state of the art review. Cancer Treat Rev. 2014;40:523–32.CrossRefPubMed Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment: where do we stand? A state of the art review. Cancer Treat Rev. 2014;40:523–32.CrossRefPubMed
6.
Zurück zum Zitat Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977;101:14–8.PubMed Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977;101:14–8.PubMed
7.
Zurück zum Zitat Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemo-therapy. Cancer. 1982;49:1221–30.CrossRefPubMed Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemo-therapy. Cancer. 1982;49:1221–30.CrossRefPubMed
8.
Zurück zum Zitat Reddick WE, Taylor JS, Fletcher BD. Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging. 1999;10:277–85.CrossRefPubMed Reddick WE, Taylor JS, Fletcher BD. Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging. 1999;10:277–85.CrossRefPubMed
9.
Zurück zum Zitat Baunin C, Schmidt G, Baumstarck K, et al. Value of diffusion-weighted images in differentiating mid-course responders to chemotherapy for osteosarcoma compared to the histological response: preliminary results. Skelet Radiol. 2012;41:1141–9.CrossRef Baunin C, Schmidt G, Baumstarck K, et al. Value of diffusion-weighted images in differentiating mid-course responders to chemotherapy for osteosarcoma compared to the histological response: preliminary results. Skelet Radiol. 2012;41:1141–9.CrossRef
10.
Zurück zum Zitat Byun BH, Kong CB, Lim I, et al. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma. J Nucl Med. 2013;54:1053–9.CrossRefPubMed Byun BH, Kong CB, Lim I, et al. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma. J Nucl Med. 2013;54:1053–9.CrossRefPubMed
11.
Zurück zum Zitat Ilhan IE, Vural G, Berberoglu S. Quantitative thallium-201 scintigraphy in childhood osteosarcoma: comparison with technetuim-99m MDP and magnetic resonance imaging in the evaluation of chemotherapeutic response. Pediatr Hematol Oncol. 2005;22:153–62.CrossRefPubMed Ilhan IE, Vural G, Berberoglu S. Quantitative thallium-201 scintigraphy in childhood osteosarcoma: comparison with technetuim-99m MDP and magnetic resonance imaging in the evaluation of chemotherapeutic response. Pediatr Hematol Oncol. 2005;22:153–62.CrossRefPubMed
12.
Zurück zum Zitat Hongtao L, Hui Z, Bingshun W, et al. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis. Surg Oncol. 2012;21:e165–70.CrossRefPubMed Hongtao L, Hui Z, Bingshun W, et al. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis. Surg Oncol. 2012;21:e165–70.CrossRefPubMed
13.
Zurück zum Zitat Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223–32.CrossRefPubMed Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusible tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223–32.CrossRefPubMed
14.
Zurück zum Zitat Verstraete KL, Lang P. Bone and soft tissue tumors: the role of contrast agents for MR imaging. Eur Radiol. 2000;34:229–46.CrossRef Verstraete KL, Lang P. Bone and soft tissue tumors: the role of contrast agents for MR imaging. Eur Radiol. 2000;34:229–46.CrossRef
15.
Zurück zum Zitat Reddick WE, Bhargava R, Taylor JS, Meyer WH, Fletcher BD. Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy. J Magn Reson Imaging. 1995;5:689–94.CrossRefPubMed Reddick WE, Bhargava R, Taylor JS, Meyer WH, Fletcher BD. Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy. J Magn Reson Imaging. 1995;5:689–94.CrossRefPubMed
16.
Zurück zum Zitat van der Woude HJ, Bloem JL, Verstraete KL, Taminiau AH, Nooy MA, Hogendoorn PC. Osteosarcoma and Ewing’s sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. AJR Am J Roentgenol. 1995;165:593–8.CrossRefPubMed van der Woude HJ, Bloem JL, Verstraete KL, Taminiau AH, Nooy MA, Hogendoorn PC. Osteosarcoma and Ewing’s sarcoma after neoadjuvant chemotherapy: value of dynamic MR imaging in detecting viable tumor before surgery. AJR Am J Roentgenol. 1995;165:593–8.CrossRefPubMed
17.
Zurück zum Zitat Guo J, Reddick WE, Glass JO, et al. Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma. Cancer. 2012;118:3776–85.CrossRefPubMed Guo J, Reddick WE, Glass JO, et al. Dynamic contrast-enhanced magnetic resonance imaging as a prognostic factor in predicting event-free and overall survival in pediatric patients with osteosarcoma. Cancer. 2012;118:3776–85.CrossRefPubMed
18.
Zurück zum Zitat Reddick WE, Wang S, Xiong X, et al. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer. 2001;91:2230–7.CrossRefPubMed Reddick WE, Wang S, Xiong X, et al. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer. 2001;91:2230–7.CrossRefPubMed
19.
Zurück zum Zitat Torricelli P, Montanari N, Spina V, et al. Dynamic contrast enhanced magnetic resonance imaging subtraction in evaluating osteosarcoma response to chemotherapy. Radiol Med. 2001;101:145–51.PubMed Torricelli P, Montanari N, Spina V, et al. Dynamic contrast enhanced magnetic resonance imaging subtraction in evaluating osteosarcoma response to chemotherapy. Radiol Med. 2001;101:145–51.PubMed
21.
Zurück zum Zitat Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.CrossRefPubMed Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–36.CrossRefPubMed
22.
Zurück zum Zitat Kawai A, Sugihara S, Kunisada T, Uchida Y, Inoue H. Imaging assessment of the response of bone tumors to preoperative chemotherapy. Clin Orthop Relat Res. 1997;337:216–25.CrossRefPubMed Kawai A, Sugihara S, Kunisada T, Uchida Y, Inoue H. Imaging assessment of the response of bone tumors to preoperative chemotherapy. Clin Orthop Relat Res. 1997;337:216–25.CrossRefPubMed
23.
Zurück zum Zitat Erlemann R, Sciuk J, Bosse A, et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology. 1990;175:791–6.CrossRefPubMed Erlemann R, Sciuk J, Bosse A, et al. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology. 1990;175:791–6.CrossRefPubMed
24.
Zurück zum Zitat Uhl M, Saueressig U, van Buiren M, et al. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Investig Radiol. 2006;41:618–23.CrossRef Uhl M, Saueressig U, van Buiren M, et al. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Investig Radiol. 2006;41:618–23.CrossRef
25.
Zurück zum Zitat Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology. 2003;228:271–8.CrossRefPubMed Dyke JP, Panicek DM, Healey JH, et al. Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. Radiology. 2003;228:271–8.CrossRefPubMed
26.
Zurück zum Zitat Fletcher BD, Hanna SL, Fairclough DL, Gronemeyer SA. Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology. 1992;184:243–8.CrossRefPubMed Fletcher BD, Hanna SL, Fairclough DL, Gronemeyer SA. Pediatric musculoskeletal tumors: use of dynamic, contrast-enhanced MR imaging to monitor response to chemotherapy. Radiology. 1992;184:243–8.CrossRefPubMed
27.
Zurück zum Zitat van der Woude HJ, Bloem JL, Schipper J, et al. Changes in tumor perfusion induced by chemotherapy in bone sarcomas: color Doppler flow imaging compared with contrast-enhanced MR imaging and three-phase bone scintigraphy. Radiology. 1994;191:421–31.CrossRefPubMed van der Woude HJ, Bloem JL, Schipper J, et al. Changes in tumor perfusion induced by chemotherapy in bone sarcomas: color Doppler flow imaging compared with contrast-enhanced MR imaging and three-phase bone scintigraphy. Radiology. 1994;191:421–31.CrossRefPubMed
28.
Zurück zum Zitat Amit P, Patro DK, Basu D, Elangovan S, Parathasarathy V. Role of dynamic MRI and clinical assessment in predicting histologic response to neoadjuvant chemotherapy in bone sarcomas. Am J Clin Oncol. 2014;37:384–90.CrossRefPubMed Amit P, Patro DK, Basu D, Elangovan S, Parathasarathy V. Role of dynamic MRI and clinical assessment in predicting histologic response to neoadjuvant chemotherapy in bone sarcomas. Am J Clin Oncol. 2014;37:384–90.CrossRefPubMed
29.
Zurück zum Zitat Toms AP, White LM, Kandel R, et al. Limitations of single slice dynamic contrast enhanced MR in pharmacokinetic modeling of bone sarcomas. Acta Radiol. 2009;50:512–20.CrossRefPubMed Toms AP, White LM, Kandel R, et al. Limitations of single slice dynamic contrast enhanced MR in pharmacokinetic modeling of bone sarcomas. Acta Radiol. 2009;50:512–20.CrossRefPubMed
30.
Zurück zum Zitat Kajihara M, Sugawara Y, Sakayama K, Kikuchi K, Mochizuki T, Murase K. Evaluation of tumor blood flow in musculoskeletal lesions: dynamic contrast-enhanced MR imaging and its possibility when monitoring the response to preoperative chemotherapy-work in progress. Radiat Med - Med Imaging Radiat Oncol. 2007;25:94–105. Kajihara M, Sugawara Y, Sakayama K, Kikuchi K, Mochizuki T, Murase K. Evaluation of tumor blood flow in musculoskeletal lesions: dynamic contrast-enhanced MR imaging and its possibility when monitoring the response to preoperative chemotherapy-work in progress. Radiat Med - Med Imaging Radiat Oncol. 2007;25:94–105.
31.
Zurück zum Zitat Ongolo-Zogo P, Thiesse P, Sau J, et al. Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadolinium-enhanced spin-echo magnetic resonance imaging and technetium-99 m skeletal angioscintigraphy. Eur Radiol. 1999;9:907–14.CrossRefPubMed Ongolo-Zogo P, Thiesse P, Sau J, et al. Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadolinium-enhanced spin-echo magnetic resonance imaging and technetium-99 m skeletal angioscintigraphy. Eur Radiol. 1999;9:907–14.CrossRefPubMed
32.
Zurück zum Zitat Karlovsek MZ, Balazic J. Evaluation of the post-rotational nystagmus test (PRN) in determining alcohol intoxication. J Anal Toxicol. 2005;29:390–3.CrossRefPubMed Karlovsek MZ, Balazic J. Evaluation of the post-rotational nystagmus test (PRN) in determining alcohol intoxication. J Anal Toxicol. 2005;29:390–3.CrossRefPubMed
33.
Zurück zum Zitat Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRefPubMed Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRefPubMed
34.
Zurück zum Zitat Whelan J, Seddon B, Perisoglou M. Management of osteosarcoma. Curr Treat Options Oncol. 2006;7:444–55.CrossRefPubMed Whelan J, Seddon B, Perisoglou M. Management of osteosarcoma. Curr Treat Options Oncol. 2006;7:444–55.CrossRefPubMed
35.
Zurück zum Zitat Pan HY, Morani A, Wang WL, et al. Prognostic factors and patterns of relapse in Ewing sarcoma patients treated with chemotherapy and R0 resection. Int J Radiat Oncol Biol Phys. 2015;92:349–57.CrossRefPubMedPubMedCentral Pan HY, Morani A, Wang WL, et al. Prognostic factors and patterns of relapse in Ewing sarcoma patients treated with chemotherapy and R0 resection. Int J Radiat Oncol Biol Phys. 2015;92:349–57.CrossRefPubMedPubMedCentral
Metadaten
Titel
Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: systematic review and meta-analysis
verfasst von
Tadahiko Kubo
Taisuke Furuta
Muhammad P. Johan
Nobuo Adachi
Mitsuo Ochi
Publikationsdatum
26.05.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Skeletal Radiology / Ausgabe 9/2016
Print ISSN: 0364-2348
Elektronische ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-016-2410-y

Weitere Artikel der Ausgabe 9/2016

Skeletal Radiology 9/2016 Zur Ausgabe

Browser's Notes

Browser’s Notes

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.